Marine Gross‐Goupil
Université de Bordeaux(FR)Inserm(FR)Inserm(FR)Centre Hospitalier Universitaire de Bordeaux(FR)Bordeaux Population Health(FR)Innovative Clinical Research(US)Hôpital Saint-André(FR)Dana-Farber Cancer Institute(US)
Publications by Year
Research Areas
Renal cell carcinoma treatment, Cancer Immunotherapy and Biomarkers, Bladder and Urothelial Cancer Treatments, Renal and related cancers, Cancer Genomics and Diagnostics
Most-Cited Works
- → Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma(2018)922 cited
- → Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma(2021)723 cited
- → Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study(2019)688 cited
- → Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial(2021)635 cited
- → Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma(2017)383 cited
- → Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer—clinical aspects and relationship with tumour response: a single-centre prospective cohort study